Literature DB >> 31298380

Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway.

Q Huang1, Y-Y Wu, S-J Xing, Z-W Yu.   

Abstract

OBJECTIVE: To explore whether micro ribonucleic acid (miR)-7 affects the resistance of breast cancer cells to adriamycin (ADR) through regulating the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-hydroxy kinase (PI3K) signaling pathway.
MATERIALS AND METHODS: MiR-7 expression was compared among MCF-10A, MCF-7 and MCF-7/ADR cells. The MCF-7/ADR cells were divided into three groups, namely miR-7 control group (MCF-7/ADR drug-resistant strains), miR-7 inhibition group (miR-7-inhibited MCF-7/ADR drug-resistant strains) and miR-7 promotion group (MCF-7/ADR drug-resistant strains transfected with miR-7), and the messenger RNA (mRNA) and protein expression levels of MCF-7/ADR were evaluated via Western blotting.
RESULTS: The expression level of miR-7 was substantially decreased in MCF-7 and MCF-7/ADR cells (p<0.05), and it was lowered more obviously in MCF-7/ADR cells than that in MCF-7 cells (p<0.05). Compared with that in miR-7 control group, miR-7 expression in miR-7 promotion group was notably raised (p<0.05), proving that the sensitivity of MCF-7/ADR cells to ADR was enhanced, while that in miR-7 inhibition group was significantly lowered (p<0.05). Compared with those in miR-7 control group, the mRNA and protein expression levels of EGFR and PI3K were elevated in miR-7 inhibition group (p<0.05), while they were lowered in miR-7 promotion group (p<0.05). Additionally, compared with those in miR-7 control group, the proliferation and apoptosis abilities of cells in miR-7 inhibition group were markedly enhanced (p<0.05) and weakened (p<0.05), respectively, while they were weakened (p<0.05) and significantly strengthened (p<0.05), respectively in miR-7 inhibition group.
CONCLUSIONS: MiR-7 plays an important role in the resistance of breast cancer cells to ADR, and its over-expression can inhibit the EGFR/PI3K signaling pathway to raise their sensitivity to the chemotherapy drug ADR.

Entities:  

Year:  2019        PMID: 31298380     DOI: 10.26355/eurrev_201906_18195

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.

Authors:  Zhuo Zhang; Hanxu Zhang; Jiao Yu; Ling Xu; Xiaocong Pang; Qian Xiang; Qianxin Liu; Yimin Cui
Journal:  Breast Cancer Res Treat       Date:  2022-06-21       Impact factor: 4.624

2.  YY1 as a promoter regulating the circ_0001946/miR-671-5p/EGFR axis to promote chemotherapy resistance in breast cancer cells.

Authors:  Ge Gao; Xiaoyan Li; Jiabeini Zhang; Hong Yu
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

3.  The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review.

Authors:  Zihan Si; Yan Zhong; Sixian Lao; Yufeng Wu; Guoping Zhong; Weiwei Zeng
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

4.  Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.

Authors:  Duanfeng Jiang; Xin Wu; Xiaoying Sun; Wei Tan; Xin Dai; Youbang Xie; Ashuai Du; Qiangqiang Zhao
Journal:  J Nanobiotechnology       Date:  2022-01-10       Impact factor: 10.435

5.  Downregulation of exosomal miR-7-5p promotes breast cancer migration and invasion by targeting RYK and participating in the atypical WNT signalling pathway.

Authors:  Zhaoyi Liang; Lu Liu; Ruixia Gao; Chengchuan Che; Ge Yang
Journal:  Cell Mol Biol Lett       Date:  2022-10-09       Impact factor: 8.702

6.  miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2.

Authors:  Tianzi Hong; Jian Ding; Wenlian Li
Journal:  Onco Targets Ther       Date:  2019-12-16       Impact factor: 4.147

Review 7.  MiR-7 in Cancer Development.

Authors:  Petra Korać; Mariastefania Antica; Maja Matulić
Journal:  Biomedicines       Date:  2021-03-23

Review 8.  MicroRNAs as a clue to overcome breast cancer treatment resistance.

Authors:  Iris Garrido-Cano; Birlipta Pattanayak; Anna Adam-Artigues; Ana Lameirinhas; Sandra Torres-Ruiz; Eduardo Tormo; Raimundo Cervera; Pilar Eroles
Journal:  Cancer Metastasis Rev       Date:  2021-09-15       Impact factor: 9.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.